RxDoctor Payments Data

Nancy Henderson-Hines, MD

Family Medicine · Fayetteville, NCNPI 1336142959

Payments from drug & device makers

$2,498in general payments, 2019–2025

Across 144 payments — averaging $17.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$758
  • Boehringer Ingelheim$353
  • AstraZeneca$258
  • Pfizer$190
  • Exact Sciences$157
  • Lilly USA, LLC$151
  • plus $631 from 11 others

What the payments were for

  • Food & beverage$2,498100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,498 in reported general payments places this provider in the 80th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$3,744
Medicare patients
130
Services billed
165

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide44$70,453
JardianceEmpagliflozin48$44,374
TrulicityDulaglutide32$36,112
LinzessLinaclotide35$28,432
EliquisApixaban40$28,309
FarxigaDapagliflozin Propanediol22$19,457
TradjentaLinagliptin11$5,420
Breo ElliptaFluticasone/Vilanterol12$4,791
Levemir FlexpenInsulin Detemir12$3,340
Humalog Kwikpen U-100Insulin Lispro16$3,293
Atorvastatin Calcium244$2,595
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$2,413
Gabapentin109$1,990
Omeprazole87$1,980
Pantoprazole Sodium130$1,806

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$758$70,45344 claims
Boehringer IngelheimJardiance, Tradjenta$353$49,79459 claims
Lilly USA, LLCTrulicity$151$36,11232 claims
AbbVieLinzess$106$28,43235 claims
PfizerEliquis$190$28,30940 claims
AstraZenecaFarxiga$258$19,45722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Fayetteville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →